Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer. - Wikidata - wikimedia - TriplyDB

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.

http://www.wikidata.org/entity/Q37022406

about

Cytotoxic and targeted therapy for hereditary cancers PARP inhibitors in ovarian cancer: evidence, experience and clinical potential Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response.Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.PI3K/AKT/mTOR Pathway in Ovarian Cancer Treatment: Are We on the Right Track?The PI3K Pathway in Human Disease.PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.Discovering new PI3Kα inhibitors with a strategy of combining ligand-based and structure-based virtual screening.PI3K pathway and Bcl-2 family. Clinicopathological features in prostate cancer.The Chemoprevention of Ovarian Cancer: the Need and the Options Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management

P2860

Q26739366-D1CFEB72-AB41-49D1-A8F4-8977FA0ABB49 Q33605912-02F0E5D0-CF85-49DB-B752-06B162DAEEA9 Q36262959-6D5B0C05-7B6E-45CA-90E9-708A91CF779A Q38605020-866D7F4B-EA3E-46AB-B426-AB0385E7B0B1 Q38757645-8EE69E1E-A05D-4989-AFF5-D78BA99E8237 Q43300329-CE6C63E9-0D4F-4EFF-BCE3-F3F345CF341C Q46546002-078EFAED-180F-4F00-8539-F420300C18ED Q47748552-66EEBFAB-EB80-49AC-B321-56F3DF72D3FB Q48299334-72A51014-AC4E-470D-9083-110955334187 Q50115573-C87DB8B2-DDED-4C98-BEAB-A6AD696FEF4C Q58579152-D29F094C-DCC4-4830-8179-47148E997E21 Q58801181-3E219EDB-F274-4D49-AD44-E18951AF9A9F

P2860

Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer.

http://www.wikidata.org/entity/Q37022406

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Effective use of PI3K inhibito ...... PIK3CA mutant ovarian cancer.

@en

Effective use of PI3K inhibito ...... PIK3CA mutant ovarian cancer.

@nl

type

label

Effective use of PI3K inhibito ...... PIK3CA mutant ovarian cancer.

@en

Effective use of PI3K inhibito ...... PIK3CA mutant ovarian cancer.

@nl

prefLabel

Effective use of PI3K inhibito ...... PIK3CA mutant ovarian cancer.

@en

Effective use of PI3K inhibito ...... PIK3CA mutant ovarian cancer.

@nl

P1433

Q37022406-FD20769E-FA81-463A-9A11-10717E9E6973

P1476

Q37022406-35BFE946-7AB0-4C18-9005-11137DEB9906

P2093

Q37022406-02E7ACF2-3E62-4C7D-A5B6-DFEA3C1A174F

Q37022406-14C65E9E-9599-45E4-A81A-853BB91B924B

Q37022406-1F7D927E-A086-4CA6-BA51-EDF654DC4FF4

Q37022406-220C7A74-CB44-467F-A963-ACD84F13C9B3

Q37022406-2F4D581D-EEB2-4C00-9B30-3BB8A8262A6C

Q37022406-73E30FC7-ADCD-419E-94DA-6A1626ACF28D

Q37022406-878750ED-2C0E-4AC6-94FB-B51D7F95F59B

Q37022406-9561B8E4-2EEB-4CE5-B93A-E9CD99752E5B

Q37022406-A52AB418-CAFA-4017-81FF-2937BDCE30B2

Q37022406-EA73E31C-1133-4E49-BA96-B2DA80A3B25A

P2860

Q37022406-01BBF257-8115-437A-8447-4D011E8F8786

Q37022406-1ACD9A90-0C02-451D-BACC-289B1055E731

Q37022406-1F7C641D-0371-440E-A80D-9D344B476479

Q37022406-20AD7783-962C-413B-BE5F-F0967C70FAE7

Q37022406-2BFECEBE-706C-4A51-A8EF-A964946FEAA8

Q37022406-32E1ADFE-D5C6-48AB-96A5-F22000936221

Q37022406-3AB87558-5DFE-45CC-86B1-0AA963201FA8

Q37022406-3CBFD6D9-F83D-432F-B9CE-05459CA30D47

Q37022406-3EA59C7D-517A-4E9F-870A-AAD0A705049B

Q37022406-4C37E03A-CD79-4BA4-8C6D-4161BE87E0E3

P304

Q37022406-9B5958AC-7927-4515-BBEF-065D3D8A64BA

P31

Q37022406-C7F61AE3-93EC-4F95-AE4F-DE984440181E

P356

Q37022406-83AFEAC2-9F4E-4188-B713-B70F2A12668A

P407

Q37022406-FB8BDE31-72D5-4E0B-BAB1-D885E0005270

P433

Q37022406-7F43A525-42C4-461F-A10A-1F44E2B27580

P478

Q37022406-7E01663D-A5AC-4442-856F-8309151EB415

P577

Q37022406-C2A45BB3-7F7D-4F9C-9A07-B1C1DBD296E9

P5875

Q37022406-6777691B-00D4-4AAB-A483-354D475444CC

P698

Q37022406-7A5F6227-AEF9-4445-B5CA-0805B9177269

P921

Q37022406-A544319A-07F2-4A55-BD02-573C165A4853

P932

Q37022406-2DD3C4AF-7C6F-4638-B656-0EBEAC4F9864

P356

ONCOTARGET.7549

P1433

P1476

Effective use of PI3K inhibito ...... PIK3CA mutant ovarian cancer.

@en

P2093

Dong Wang

http://www.w3.org/2001/XMLSchema#string

Hailing Cheng

http://www.w3.org/2001/XMLSchema#string

Jean J Zhao

http://www.w3.org/2001/XMLSchema#string

Min Wang

http://www.w3.org/2001/XMLSchema#string

Nan Jiang

http://www.w3.org/2001/XMLSchema#string

Pixu Liu

http://www.w3.org/2001/XMLSchema#string

Thomas M Roberts

http://www.w3.org/2001/XMLSchema#string

Xiaoqing Wang

http://www.w3.org/2001/XMLSchema#string

Xing Bian

http://www.w3.org/2001/XMLSchema#string

Yuan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Resistance to therapy caused by intragenic deletion in BRCA2

Targeting the phosphoinositide 3-kinase pathway in cancer

Drug combination studies and their synergy quantification using the Chou-Talalay method

PI3K and cancer: lessons, challenges and opportunities

Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair.

Three-dimensional culture models of normal and malignant breast epithelial cells.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cells.

P304

13153-13166

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.7549

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2016-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

295911200

http://www.w3.org/2001/XMLSchema#string

P698

26909613

http://www.w3.org/2001/XMLSchema#string

P921

P932

4914348

http://www.w3.org/2001/XMLSchema#string